BIRC5 and glioblastoma: Brd4 inhibition abrogated an the constitutively active mutant form of the EGFR receptor (EGFRvIII)-induced transcription expression of BIRC5 and eliminated IL-6-mediated therapy resistance in glioblastoma [58].